{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"GeneralNote": [], "SpaceFlightMission": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "KeywordList": [], "PMID": "23975654", "DateCompleted": {"Year": "2014", "Month": "05", "Day": "14"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "08"}, "Article": {"ELocationID": ["10.1007/s40261-013-0117-6"], "ArticleDate": [], "Language": ["eng"], "Journal": {"ISSN": "1179-1918", "JournalIssue": {"Volume": "33", "Issue": "10", "PubDate": {"Year": "2013", "Month": "Oct"}}, "Title": "Clinical drug investigation", "ISOAbbreviation": "Clin Drug Investig"}, "ArticleTitle": "Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.", "Pagination": {"StartPage": "727", "EndPage": "736", "MedlinePgn": "727-36"}, "Abstract": {"AbstractText": ["The identification and quantification of potential drug-drug interactions is important for avoiding or minimizing the interaction-induced adverse events associated with specific drug combinations. Clinical studies in healthy subjects were performed to evaluate potential pharmacokinetic interactions between vortioxetine (Lu AA21004) and co-administered agents, including fluconazole (cytochrome P450 [CYP] 2C9, CYP2C19 and CYP3A inhibitor), ketoconazole (CYP3A and P-glycoprotein inhibitor), rifampicin (CYP inducer), bupropion (CYP2D6 inhibitor and CYP2B6 substrate), ethinyl estradiol/levonorgestrel (CYP3A substrates) and omeprazole (CYP2C19 substrate and inhibitor).", "The ratio of central values of the test treatment to the reference treatment for relevant parameters (e.g., area under the plasma concentration-time curve [AUC] and maximum plasma concentration [C max]) was used to assess pharmacokinetic interactions.", "Co-administration of vortioxetine had no effect on the AUC or C max of ethinyl estradiol/levonorgestrel or 5'-hydroxyomeprazole, or the AUC of bupropion; the 90\u00a0% confidence intervals for these ratios of central values were within 80-125\u00a0%. Steady-state AUC and C max of vortioxetine increased when co-administered with bupropion (128 and 114\u00a0%, respectively), fluconazole (46 and 15\u00a0%, respectively) and ketoconazole (30 and 26\u00a0%, respectively), and decreased by 72 and 51\u00a0%, respectively, when vortioxetine was co-administered with rifampicin. Concomitant therapy was generally well tolerated; most adverse events were mild or moderate in intensity.", "Dosage adjustment may be required when vortioxetine is co-administered with bupropion or rifampicin."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Pharmacology, Takeda Development Center Americas, One Takeda Parkway, Deerfield, IL, 60015, USA, grace.chen@takeda.com."}], "Identifier": [], "LastName": "Chen", "ForeName": "Grace", "Initials": "G"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lee", "ForeName": "Ronald", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "H\u00f8jer", "ForeName": "Astrid-Maria", "Initials": "AM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Buchbjerg", "ForeName": "Jeppe Klint", "Initials": "JK"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Serenko", "ForeName": "Michael", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhao", "ForeName": "Zhen", "Initials": "Z"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Clin Drug Investig", "NlmUniqueID": "9504817", "ISSNLinking": "1173-2563"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antifungal Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Contraceptives, Oral, Hormonal"}, {"RegistryNumber": "0", "NameOfSubstance": "Enzyme Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Piperazines"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfides"}, {"RegistryNumber": "01ZG3TPX31", "NameOfSubstance": "Bupropion"}, {"RegistryNumber": "3O2K1S3WQV", "NameOfSubstance": "Vortioxetine"}, {"RegistryNumber": "8VZV102JFY", "NameOfSubstance": "Fluconazole"}, {"RegistryNumber": "KG60484QX9", "NameOfSubstance": "Omeprazole"}, {"RegistryNumber": "R9400W927I", "NameOfSubstance": "Ketoconazole"}, {"RegistryNumber": "VJT6J7R4TR", "NameOfSubstance": "Rifampin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Antidepressive Agents"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Antifungal Agents"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Bupropion"}, {"QualifierName": [], "DescriptorName": "Cohort Studies"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Contraceptives, Oral, Hormonal"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": ["physiology"], "DescriptorName": "Drug Interactions"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Enzyme Induction"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Enzyme Inhibitors"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Fluconazole"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Ketoconazole"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Omeprazole"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Piperazines"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Rifampin"}, {"QualifierName": [], "DescriptorName": "Single-Blind Method"}, {"QualifierName": ["blood", "pharmacokinetics"], "DescriptorName": "Sulfides"}, {"QualifierName": [], "DescriptorName": "Vortioxetine"}, {"QualifierName": [], "DescriptorName": "Young Adult"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bang-Andersen B, Ruhland T, J\u00f8rgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2001;54:3206\u20133221. doi: 10.1021/jm101459g.", "ArticleIdList": ["10.1021/jm101459g", "21486038"]}, {"Citation": "M\u00f8rk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340:666\u2013675. doi: 10.1124/jpet.111.189068.", "ArticleIdList": ["10.1124/jpet.111.189068", "22171087"]}, {"Citation": "Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73:953\u2013959. doi: 10.4088/JCP.11m07470.", "ArticleIdList": ["10.4088/JCP.11m07470", "22901346"]}, {"Citation": "Jain R, Mahableshwarkar A, Jacobson P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5\u00a0mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16:313\u2013321. doi: 10.1017/S1461145712000727.", "ArticleIdList": ["10.1017/S1461145712000727", "22963932"]}, {"Citation": "Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5\u00a0mg and 5\u00a0mg vortioxetine (LuAA21004) versus placebo for 8\u00a0weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29:217\u2013226. doi: 10.1185/03007995.2012.761600.", "ArticleIdList": ["10.1185/03007995.2012.761600", "23252878"]}, {"Citation": "Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet. 2003;42:153\u2013178. doi: 10.2165/00003088-200342020-00004.", "ArticleIdList": ["10.2165/00003088-200342020-00004", "12537515"]}, {"Citation": "Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361\u2013390. doi: 10.2165/00003088-199835050-00003.", "ArticleIdList": ["10.2165/00003088-199835050-00003", "9839089"]}, {"Citation": "Hisaka A, Kusama M, Ohno Y, et al. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet. 2009;48:653\u2013666. doi: 10.2165/11317220-000000000-00000.", "ArticleIdList": ["10.2165/11317220-000000000-00000", "19743887"]}, {"Citation": "Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86:203\u2013215. doi: 10.1159/000319744.", "ArticleIdList": ["10.1159/000319744", "20829645"]}, {"Citation": "Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012;40:1357\u20131365. doi: 10.1124/dmd.112.044610.", "ArticleIdList": ["10.1124/dmd.112.044610", "22496396"]}, {"Citation": "Areberg J, S\u00f8gaard B, H\u00f8jer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol. 2012;111:198\u2013205.", "ArticleIdList": ["22448783"]}, {"Citation": "Nilausen D, H\u00f8jer A-M, Bendahl L. Absorption, metabolism, and excretion of an oral dose of [14C]-Lu AA21004 50\u00a0mg in healthy men. J Clin Pharmacol. 2009;49:1113."}, {"Citation": "Brown HS, Galetin A, Hallifax D, et al. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet. 2006;45:1035\u20131050. doi: 10.2165/00003088-200645100-00006.", "ArticleIdList": ["10.2165/00003088-200645100-00006", "16984215"]}, {"Citation": "von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet. 1995;29(suppl 1):33\u201344. doi: 10.2165/00003088-199500291-00007.", "ArticleIdList": ["10.2165/00003088-199500291-00007", "8846621"]}, {"Citation": "Zhou S, Yung Chan S, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279\u2013304.", "ArticleIdList": ["15762770"]}, {"Citation": "Wang Y, Wojtkowski T, Hanson E, et al. An open-label, multiple-dose study in healthy adults to assess the drug interaction potential of Lu AA21004 using the Indiana cocktail. J Clin Pharmacol. 2009;49:1114."}, {"Citation": "Spina E, Trifiro G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39\u201367. doi: 10.2165/11594710-000000000-00000.", "ArticleIdList": ["10.2165/11594710-000000000-00000", "22171584"]}, {"Citation": "Areberg J, Naik H, Chen G, Pedersen KB, Vakilynejad M. A population pharmacokinetic meta-analysis of vortioxetine (Lu AA21004) in healthy subjects. Poster presented at the 12th International Forum on Mood and Anxiety Disorders (IFMAD), Barcelona, Spain, November 7\u20139, 2012."}], "ReferenceList": []}], "History": [{"Year": "2013", "Month": "8", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "8", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "5", "Day": "16", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["23975654", "PMC3775155", "10.1007/s40261-013-0117-6"]}}]}